(VIANEWS) – Shares of Atrion (NASDAQ: ATRI) dropped by a staggering 17.1% in 5 sessions from $685.16 at -17.1, to $568.00 at 10:42 EST on Wednesday, after two successive sessions in a row of losses. NASDAQ is dropping 0.4% to $11,409.22, after three successive sessions in a row of losses.
Atrion’s last close was $568.00, 27.53% below its 52-week high of $783.80.
About Atrion
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and products for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
Earnings Per Share
As for profitability, Atrion has a trailing twelve months EPS of $17.44.
PE Ratio
Atrion has a trailing twelve months price to earnings ratio of 32.57. Meaning, the purchaser of the share is investing $32.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.34%.
Volume
Today’s last reported volume for Atrion is 120 which is 97.52% below its average volume of 4572.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Atrion’s stock is considered to be overbought (>=80).
More news about Atrion (ATRI).
